A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinsons Disease Complicated by Motor Fluctuations (OFF Episodes)
A study for patients with Parkinson's Disease using study drug Levodopa (APL-130277)
Sponsor: Cynapsus
Enrolling: Male and Female Patients
IRB Number: AAAP9307
U.S. Govt. ID: NCT02469090
Contact: Amber Servi: 212-305-3938 / ads2178@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the effectiveness of investigational drug APL-130277 for patients with Parkinson's disease. APL-130277 is an investigational drug, which means that the study drug is currently being tested. It is not approved by the U.S. Food and Drug Administration (FDA). The active ingredient in APL-130277 is apomorphine, a medication that has been used in an injectable form for many years to treat OFF episodes in patients with Parkinsons disease (PD). APL-130277 is a fast acting thin film formulation of apomorphine that is placed under the tongue, similar to a breath strip used to freshen your breath. APL-130277 is intended to be an alternative to the injectable form of apomorphine, whichis known under the brand name APOKYN, and is given as an injection under the skin.
This study is closed
Cheryl Waters, MD
Do You Qualify?
Have you been diagnosed with Parkinson's Disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Amber Servi